结直肠癌患者血清 p53 抗体作为肿瘤标志物的再评估。
Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.
机构信息
Department of Surgery, National Tokyo Medical Center, Tokyo, Japan.
出版信息
Surg Today. 2012 Jan;42(2):164-8. doi: 10.1007/s00595-011-0044-1. Epub 2011 Nov 11.
PURPOSE
We reevaluated the serum p53 antibody (S-p53Ab) ELISA kit, which was approved as a tumor marker of colon cancer in the Japanese Health Insurance System in 2007.
METHODS
S-p53Ab was measured as a tumor marker in 154 colorectal cancer patients, and the results were categorized by clinical and pathological variables. We then compared the positive frequency of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate 19-9 (CA19-9).
RESULTS
S-p53Ab was positive in 33.1% of the colorectal cancer patients. The positive rate was significantly higher in patients with lymph nodes metastasis (P = 0.025) and lymphatic invasion (P = 0.023). In patients with stage I colorectal cancer, the positive rate of S-p53Ab (23.7%) was significantly higher than that of CEA (5.3%) or CA19-9 (7.9%).
CONCLUSION
The approved kit for S-p53Ab testing was found to be an effective tumor marker of colorectal cancer. The positive rate of S-p53Ab was significantly higher in patients with cancer involvement of the lymphoid tissues. The positive rate of S-p53Ab was higher than that of CEA and CA19-9 in patients with stage I colorectal cancer, suggesting that the S-p53Ab is a useful tumor marker for patients with early-stage disease.
目的
我们重新评估了血清 p53 抗体（S-p53Ab）ELISA 试剂盒，该试剂盒于 2007 年在日本健康保险系统中被批准为结肠癌的肿瘤标志物。
方法
我们将 S-p53Ab 作为肿瘤标志物在 154 例结直肠癌患者中进行了检测，并按临床和病理变量对结果进行了分类。然后，我们比较了 S-p53Ab、癌胚抗原（CEA）和糖类抗原 19-9（CA19-9）的阳性率。
结果
结直肠癌患者中 S-p53Ab 阳性率为 33.1%。淋巴结转移（P = 0.025）和淋巴管浸润（P = 0.023）患者的阳性率显著较高。在 I 期结直肠癌患者中，S-p53Ab 的阳性率（23.7%）显著高于 CEA（5.3%）或 CA19-9（7.9%）。
结论
用于 S-p53Ab 检测的试剂盒被发现是结直肠癌的一种有效的肿瘤标志物。S-p53Ab 在涉及淋巴组织的癌症患者中的阳性率显著较高。在 I 期结直肠癌患者中，S-p53Ab 的阳性率高于 CEA 和 CA19-9，表明 S-p53Ab 是早期疾病患者的一种有用的肿瘤标志物。
Zotero 插件